Penning-van Beest F J, van Meegen E, Rosendaal F R, Stricker B H
Pharmaco-epidemiology Unit, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Thromb Haemost. 2001 Aug;86(2):569-74.
The risk of hemorrhage when using coumarin anticoagulants sharply increases when the International Normalised Ratio (INR) is > or =6.0. We performed a prospective cohort study with a nested case-control design among 17,056 outpatients of an anticoagulation clinic to determine the incidence of overanticoagulation and to study the association between overanticoagulation and characteristics of anticoagulant therapy and comorbidity. The incidence rate of an INR > or =6.0 was 7.8 per 10,000 treatment days in prevalent users on the starting date and 22.5 per 10,000 treatment days in incident users during the study period. 300 cases with an INR > or =6.0 were compared with 302 randomly selected matched controls with an INR within the target zone. Patients on acenocoumarol had an increased risk of an INR > or =6.0 compared to patients on phenprocoumon. Regarding comorbidity, impaired liver function, congestive heart failure, diarrhea and fever were risk factors for overanticoagulation. Increased monitoring of INR values if risk factors are present or avoidance of risk factors could prevent excess anticoagulation and potential bleeding complications.
当国际标准化比值(INR)≥6.0时,使用香豆素类抗凝剂时出血风险会急剧增加。我们在一家抗凝门诊的17056名门诊患者中进行了一项采用巢式病例对照设计的前瞻性队列研究,以确定抗凝过度的发生率,并研究抗凝过度与抗凝治疗特征及合并症之间的关联。在起始日期时,现用者中INR≥6.0的发生率为每10000个治疗日7.8例,在研究期间新用者中为每10000个治疗日22.5例。将300例INR≥6.0的病例与302例随机选取的INR在目标范围内的匹配对照进行比较。与使用苯丙香豆素的患者相比,使用醋硝香豆素的患者发生INR≥6.0的风险增加。关于合并症,肝功能受损、充血性心力衰竭、腹泻和发热是抗凝过度的危险因素。如果存在危险因素则增加INR值监测或避免危险因素可预防抗凝过度及潜在的出血并发症。